Finance

Lists
Q2 2026 earnings • released • EPS beat +0.95% • Revenue miss -1.75%
See results
ZTS:NYSE
Zoetis Inc
$72.66
-5.97%
(-4.61) 1D
$73.07
+0.56% (+0.41)
After hours
Closed: Aug 7, 4:02:20 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZTS...
Open
$77.92
High
$79.25
Low
$72.19
Mkt. cap
30.46B
Avg. vol.
6.61M
Volume
12.78M
Dividend
2.92%
Quarterly dividend
$0.53
Ex-dividend date
Jul 20, 2026
P/E ratio
11.95
52-wk high
$160.48
52-wk low
$71.47
EPS
$6.08
Beta
0.74
Shares outstanding
419.23M
No. of employees
14K
Open
$77.92
High
$79.25
Low
$72.19
Mkt. cap
30.46B
Avg. vol.
6.61M
Volume
12.78M
Dividend
2.92%
Quarterly dividend
$0.53
Ex-dividend date
Jul 20, 2026
P/E ratio
11.95
52-wk high
$160.48
52-wk low
$71.47
EPS
$6.08
Beta
0.74
Shares outstanding
419.23M
No. of employees
14K
News stories
From sources across the web
Profile
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total revenue. Contemporaneous with the spinoff in June 2013 S&P Dow Jones Indices announced that Zoetis would replace First Horizon National Corporation in the S&P 500 stock market index. Wikipedia
About Zoetis Inc
CEOKristin C. Peck
Employees14.5K
Founded1952
HeadquartersParsippany-Troy Hills, New Jersey, United States
SectorPharmaceutical industry
Websitezoetis.com
Analyst ratings
Based on 10 analysts giving stock ratings to ZTS in the past 3 months
Buy
Buy
4
Hold
6
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for ZTS in the last 3 months.
Highest
Current $72.66
$112.00 (+54.14%)
Average
$92.29 (+27.02%)
Lowest
$80.00 (+10.10%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jonathan Block
Stifel Nicolaus
Hold
Maintained
$85.00
+17%
08/07/2026
Andrea Alfonso
UBS
Hold
Reiterated
$80.00
+10.1%
08/07/2026
Erin Wright
Morgan Stanley
Buy
Maintained
$85.00
+17%
08/07/2026
Ryan Daniels
William Blair
Hold
Downgraded
-
-
08/06/2026
Brandon Vazquez
William Blair
Hold
Downgraded
-
-
08/08/2026
Michael Ryskin
Bank of America Securities
Hold
Maintained
-
-
07/28/2026
Sidharth Sahoo
HSBC
Buy
Maintained
$95.00
+30.7%
07/06/2026
Glen Santangelo
Barclays
Hold
Maintained
$85.00
+17%
07/01/2026
Steve Scala
TD Cowen
Buy
Reiterated
$104.00
+43.1%
06/30/2026
Jasper Hellweg
Argus Research
Hold
Downgraded
-
-
05/26/2026
Daniel Grosslight
Citi
Buy
Maintained
$112.00
+54.1%
05/18/2026
Chris Schott
J.P. Morgan
Buy
Reiterated
$130.00
+78.9%
05/08/2026
Scott Schoenhaus
KeyBanc
Hold
Maintained
-
-
05/08/2026
Thomas DeBourcy
Nephron
Hold
Downgraded
$131.00
+80.3%
03/05/2026
Mark Massaro
BTIG
Buy
Reiterated
$160.00
+120.2%
02/26/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$1.87 / $1.85
+0.95%beat
Revenue / Est. (USD)
2.47B / 2.51B
-1.75%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
2.40B
2.39B
2.26B
2.47B
Cost of goods sold
682.00M
711.00M
640.00M
670.00M
Cost of revenue
682.00M
711.00M
640.00M
670.00M
Research and development expenses
170.00M
199.00M
180.00M
173.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
572.00M
618.00M
584.00M
589.00M
Operating expense
774.00M
848.00M
795.00M
793.00M
Total operating expenses
1.46B
1.56B
1.44B
1.46B
Operating income
944.00M
828.00M
827.00M
1.00B
Other non operating income
-
-6.00M
-1.00M
5.00M
EBT including unusual items
887.00M
761.00M
758.00M
866.00M
EBT excluding unusual items
899.00M
780.00M
779.00M
949.00M
Income tax expense
166.00M
158.00M
157.00M
175.00M
Effective tax rate
18.71%
20.76%
20.71%
20.21%
Other operating expenses
-
-
-
-
Net income
721.00M
603.00M
601.00M
691.00M
Net profit margin
30.04%
25.26%
26.57%
28.00%
Earnings per share
1.70
1.48
1.53
1.87
Interest and investment income
26.00M
25.00M
21.00M
-
Interest expense
-58.00M
-57.00M
-62.00M
-61.00M
Net interest expenses
-32.00M
-32.00M
-41.00M
-61.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.07B
903.00M
946.00M
1.12B
Gain or loss from assets sale
-
-
-6.00M
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps